Eli Lilly and Company (LLY)
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
Once the go-to location for global drugmakers, Europe is losing market share to aggressive U.S. trade policies and China's growth as a biotech hub. Europe's share of global R&D has been cut in half over the past 35 years, with more companies prioritizing investments in the U.S. and China.
Eli Lilly's Weight-Loss Pill Hits the Shelves. It's a Turning Point for the Stock.
The pharmaceutical's Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.
Eli Lilly Weight-Loss Pill Becomes Available in U.S.
Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said.
Eli Lilly (LLY) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, Eli Lilly (LLY) closed at $953.3, indicating a +2.39% shift from the previous trading day.
3 Reasons To Buy Eli Lilly Now
Eli Lilly (LLY) remains a Buy despite a recent 12% price decline, supported by strategic developments and valuation upside, even as it faces challenges. LLY faces near-term headwinds from Zepbound price cuts, slower revenue growth guidance, and acquisition-related earnings drag. FDA approval of orforglipron and the Centessa (CNTA) acquisition, however, expand LLY's cardio-metabolic and neuroscience portfolios respectively and enhance long-term growth prospects.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly (LLY) Stock Sinks As Market Gains: Here's Why
In the most recent trading session, Eli Lilly (LLY) closed at $935.58, indicating a -1.98% shift from the previous trading day.
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
Eli Lilly And Company (NYSE: LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopolitical tensions weigh on broader markets.
Lilly (LLY) Surges 3.8%: Is This an Indication of Further Gains?
Lilly (LLY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Lilly gains after FDA approves weight-loss pill, sizing down investor doubts
Eli Lilly shares jumped nearly 6% on Wednesday after the U.S. Food and Drug Administration approved its weight-loss pill, Foundayo, marking a significant milestone in the drugmaker's efforts to expand its foothold in the lucrative obesity market.
Eli Lilly weight loss pill Foundayo approved by FDA, shares rise
Eli Lilly and Co (NYSE:LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity or those who are overweight with weight-related medical conditions, sending its shares more than 5% higher on Wednesday afternoon.
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
Lilly (LLY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
